GlassScriptPhysician profile
Farrukh Hashmi
NPI 1467497222
$6,104.61
in general payments reported to CMS, 2019-2025
24 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $445 · 2021: $959 · 2022: $1,058 · 2023: $713 · 2024: $1,663 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899 · Education: $39.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.87 |
| Education | $39.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,079.87 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $967.20 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $830.11 | 2019-2022 | |
| Alkermes, INC. | $619.20 | 2019-2024 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $412.88 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $359.27 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $334.43 | 2022-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $304.75 | 2019-2025 | Spravato |
| Abbvie INC. | $192.63 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $168.04 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $158.42 | 2022-2024 | Rexulti |
| Janssen Scientific Affairs, LLC | $130.40 | 2025 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $127.94 | 2023-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $115.00 | 2019-2022 | |
| Eisai INC. | $64.56 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $47.52 | 2022 | |
| Allergan, INC. | $40.43 | 2019-2020 | |
| Almatica Pharma LLC | $31.59 | 2021 | |
| Jazz Pharmaceuticals INC. | $24.05 | 2021 | |
| Corium, LLC | $23.80 | 2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $20.73 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.66 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $16.60 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farrukh Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.